WASHINGTON – U.S. Sen. Jon Husted questioned witnesses at a Senate hearing Wednesday about cases where men allegedly slipped mifepristone to women without their consent, citing examples from Ohio and Texas to argue for reinstating in-person dispensing requirements for the abortion drug.

“I’ve seen some of the horrors of men who are trying to use the drug to end pregnancies against the will of the woman that they give the drug to,” Husted told the Senate Health, Education, Labor and Pensions Committee during its hearing titled “Protecting Women’s Health: Exposing the Dangers of Chemical Abortion Drugs.”

“This is not the choice of a woman controlling her own body,” he said.

Ohio case among examples cited

Husted presented two cases to illustrate his concerns, including one where Toledo-area doctor Hassan-James Abbas was indicted after he was accused of obtaining the drug from an out-of-state telemedicine provider and used it to secretly end his girlfriend’s pregnancy.

Abbas is accused of ordering mifepristone and misoprostol after the woman said she didn’t want an abortion by using his estranged wife’s identity and then forcing them into the woman’s mouth while she slept. His license to practice medicine has been suspended.

Husted also cited a 2025 Texas case where a man is accused of obtaining mifepristone and slipping it into the hot chocolate of a woman he had impregnated, and who was refusing to get an abortion.

Senator’s personal connection

Husted opened his questioning by sharing his own adoption story, which he has discussed publicly before.

“I started out in foster care, was adopted, and know that my birth mother was under a lot of pressure to have an abortion, and thankfully for me, she didn’t,” the Republican senator said. “I know that my biological father had pressured her to do so, and she chose an adoption.”

He said reflecting on his background made him question whether he would exist today if mifepristone had been as easily accessible when his birth mother was pregnant. “I would like to think that my birth mother would have still chosen to have an adoption, but I’ve seen some of the horrors of men who are trying to use the drug to end pregnancies against the will of the woman that they give the drug to,” he said.

Question of access vs. safety

Louisiana Attorney General Liz Murrill, a witness at the hearing, told Husted that putting an in-person dispensing requirement in place would address the problem.

Murrill responded that Louisiana believes “putting the in-person dispensing requirement back in place would substantially protect women.” She noted that Louisiana has placed the drugs on its state controlled substances list “so that we can track who’s prescribing them and make sure that there’s some accountability for the use of these medications.”

The hearing featured sharply contrasting testimony about mifepristone’s safety and the impact of FDA regulations governing its distribution.

In her written testimony, Murrill argued that the Biden administration’s 2023 decision to remove in-person dispensing requirements for mifepristone was “not a legal or medically-informed decision, but a purely political one.”

She presented cases from Louisiana where she said women were harmed by mail-order abortion drugs, including a teenager allegedly coerced by her mother and cases where women experienced medical emergencies.

Testimony from Dr. Monique Chireau Wubbenhorst, an Adjunct Professor, Indiana University School of Medicine, outlined various complications associated with medication abortion and argued that “telemedicine abortion” and “self-administered abortion are unsafe and endanger women.”

However, Dr. Nisha Verma of Physicians for Reproductive Health stated that “the science on mifepristone’s safety and effectiveness is longstanding and settled,” noting the drug “has been rigorously researched and proven safe and effective in hundreds of high-quality, peer-reviewed studies.”

She testified that serious adverse events with medication abortion “are very rare, consistently occurring in well under one percent of cases.”